Simcere Pharmaceutical Group announced the appointment of Dr. Zang Jingwu as Chief Scientific Officer of the Company, effective October 8, 2013.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
5.8 HKD | +2.11% | +2.12% | -13.97% |
Apr. 25 | Simcere Pharmaceutical’ Profit Down 23% in 2023 | MT |
Apr. 10 | Simcere Pharmaceutical's Cancer Drug Gets Fast Track Designation From US FDA | MT |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-13.97% | 1.86B | |
+20.52% | 44.39B | |
+20.08% | 22.46B | |
+17.96% | 15.04B | |
+19.53% | 13.98B | |
+55.16% | 13.15B | |
-10.55% | 6.89B | |
-0.05% | 6.79B | |
+14.03% | 5.71B | |
-8.87% | 5.73B |
- Stock Market
- Equities
- 2096 Stock
- News Simcere Pharmaceutical Group Limited
- Simcere Pharmaceutical Group. Appoints Zang Jingwu as Chief Scientific Officer